行情

NAVB

NAVB

Navidea生物制药
AMEX

实时行情|Nasdaq Last Sale

0.7899
+0.0121
+1.56%
交易中 11:51 04/02 EDT
开盘
0.7800
昨收
0.7778
最高
0.8000
最低
0.7800
成交量
1.51万
成交额
--
52周最高
4.200
52周最低
0.4900
市值
1,614.52万
市盈率(TTM)
-1.0042
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NAVB价格均价为3.500,最高价位4.000,最低价为3.000。

EPS

NAVB 新闻

更多
  • Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navideas Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates
  • Business Wire · 2天前
  • Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMT
  • Thomson Reuters StreetEvents · 03/24 20:19
  • Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®
  • Business Wire · 03/20 12:00
  • Navidea Bio +26% premarket on Lymphoseek patent extension
  • Seeking Alpha - Article · 03/20 11:37

所属板块

生物技术和医学研究
+2.24%
制药与医学研究
+1.50%

热门股票

代码
价格
涨跌幅

NAVB 简况

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).
展开

微牛提供Navidea Biopharmaceuticals Inc(AMEX-NAVB)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NAVB股票新闻,以帮助您做出投资决策。